Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D. Remmy
A First-In-Human Trial of the Novel Multi-Action Therapy Tinostamustine (Edo-S101) in Patients With Relapsed/Refractory (R/R) Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Early Data From a Phase Ii Trial of Pembrolizumab (Pem) and Entinostat (Ent) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (Hl) and Follicular Lymphoma (Fl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Global Pivotal Phase 2 Trial of the Cd19-Targeted Therapy Ctl019 in Adult Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)-An Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Retreatment With Nivolumab in Patients With R/R Classical Hodgkin Lymphoma After Discontinuation of the Therapy With Immune Checkpoint Inhibitors
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
R-Ivac Salvage Therapy in Relapsed and Refractory DLBCL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rituximab, Bendamustine and Cytarabine (R-Bac) in Patients With Relapsed-Refractory Aggressive B-Cell Lymphoma
American Journal of Hematology
Hematology
Oral Azacytidine (Aza) and Romidepsin (R) Reveals Promising Activity in Patients With Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (Ptcl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
